You are here

  • Home
  • Archive
  • Volume 20, Issue 4
  • Clinical Significance of Serum CA-125 and Soluble Tumor Necrosis Factor Receptor Type I in Cervical Adenocarcinoma Patients

Article Text

Article menu
Download PDFPDF
Cervical Cancer
Clinical Significance of Serum CA-125 and Soluble Tumor Necrosis Factor Receptor Type I in Cervical Adenocarcinoma Patients
  1. Beata Kotowicz, PhD*,
  2. Janina Kaminska, PhD*,
  3. Malgorzata Fuksiewicz, PhD*,
  4. Maria Kowalska, PhD*,
  5. Joanna Jonska-Gmyrek, PhD†,
  6. Krzysztof Gawrychowski, PhD‡,
  7. Janusz Sobotkowski, PhD§,
  8. Maciej Skrzypczak, PhD∥,
  9. Jozef Starzewski, MD, PhD and
  10. Mariusz Bidzinski, MD, PhD†
  1. *Departments of Tumor Markers,
  2. †Gynecologic Oncology, and
  3. ‡Gynecology of the Maria Sklodowska-Curie Cancer Center and Institute of Oncology, Warsaw;
  4. §Department of Gynecological Radiotherapy of Regional Oncological Center of the Copernicus Memorial Hospital, Lodz;
  5. ∥Second Department of Gynecology Medical University of Lublin, Lublin; and
  6. Department of Gynecology of Holycross Cancer Center, Kielce, Poland.
  1. Address correspondence and reprint requests to Beata Kotowicz, PhD, Department of Tumor Markers, Cancer Center and Institute of Oncology, 02-781 Warsaw, ul. Roentgena 5, Poland. E-mail: bkotowicz{at}coi.pl.

Abstract

Hypothesis: The purpose of this study was to answer the question whether the measurement of the pretreatment tumor markers and cytokine levels would be of clinical use in patients with cervical adenocarcinoma.

Methods: CA-125, carcinoembryonic antigen (CEA), and squamous cell carcinoma (SCC), as well as interleukin 6 (IL-6), IL-8, vascular endothelial growth factor, IL-1 receptor antagonist, soluble tumor necrosis factor receptor type I (sTNF RI), and sTNF RII, were assessed in the sera of 120 cervical adenocarcinoma patients.

Results: CA-125 presented a better diagnostic sensitivity than did CEA and SCC, whereas the concentration of most cytokines, except for sTNF RII, revealed higher sensitivity, than did the standard tumor markers. The highest sensitivity was found for sTNF RI. The concentrations of the examined parameters were found to be significantly higher in patients with advanced stage (IIB-IV) as compared with patients with I-IIA stage. [Float1]Serum concentration of IL-6 was the only one that differs significantly, depending on the histological grade. During the 3-year follow-up, 25 patients relapsed, and 73 patients were disease-free. Significantly higher pretreatment serum concentrations of the examined parameters (except for SCC and IL-1 receptor antagonist) were found in patients who developed recurrences. Soluble tumor necrosis factor receptor type I and CA-125 were found to present the highest sensitivity, with areas under the receiver operating characteristic curve of 0.833 and 0.809, respectively. As the result of univariate analysis, CA-125, CEA, sTNF RII, IL-6, sTNF RI, and clinical stage were considered factors of poor prognosis. Multivariate analysis has proven that CA-125 and clinical stage were the only significant independent prognostic factors of the disease-free survival.

Conclusion: CA-125 is an independent prognostic factor for disease-free survival. Our results have also demonstrated that sTNF RI is probably the most useful marker in cervical adenocarcinoma patients, especially in the early stages of disease.

  • Tumor marker
  • Cytokine
  • Cervical adenocarcinoma
  • Disease-free survival

https://doi.org/10.1111/IGC.0b013e3181d5c27a

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • The study was supported by grant 2 P05E 082 30 of the Ministry of Science and Higher Education in Poland.

    • The study was approved by the local ethics committee at the Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology in Warsaw. Each patient signed informed consent for inclusion into the study.